- Patents. All of PonderaÔÇÖs formulations and products are covered under a series of patents and patent applications, insuring proprietary status and patent protection against competition.┬á┬á On February 12, 2013 the U.S. Patent Office Issued Pat. No. 8,372,414 to Pondera for Anxiety Relief.
- Partnership and licensing Agreements. Pondera will consider entering into appropriate and mutually beneficial partnership and licensing agreements in the United States, Canada, Europe, South America, Asia and Africa for Endorphinate┬« commercialization.
- Manufacturing. Pondera is seeking manufacturers in the United States, Canada, Europe, South America, Asia and Africa to produce Endorphinate┬« for these markets.
- Distribution and sales. Pondera is seeking to establish distribution and sales relationship with companies in the United States, Canada, Europe, South America, Asia and Africa to distribute and sell Endorphinate┬«.
For access to┬áConfidential Financial, Scientific, Research and Strategic Partnership Information, ┬áplease contact:
William E. Crain, President & CEO
Pondera Pharmaceuticals, Inc.
209 Chadsey Road, Pownal ME 04069